BioSpace News Archive

Revvity, Inc. will present at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024 at 8:40 a.m. PT in Las Vegas, NV.

Apollomics Inc. announced that its partner in China, Avistone Biotechnology Co. Ltd., received approval from the National Medical Products Administration of China for vebreltinib for the treatment of adult patients with isocitrate dehydrogenase mutant astrocytoma or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion gene and have failed previous treatments.

Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present data from its respiratory portfolio, including vaccines and vaccine candidates against COVID-19.

Onconic Therapeutics today announced that the Ministry of Food and Drug Safety (MFDS) of Korea has approved JAQBO (zastaprazan citrate) for the treatment of erosive gastroesophageal reflux disease (GERD) in adults.

Bristol Myers Squibb (NYSE: BMY) today reports results for the first quarter of 2024, which reflect meaningful progress in the company’s growth portfolio and pipeline.

Apyx Medical Corporation today announced that financial results for the first quarter of fiscal year 2024 will be released before the market opens on Thursday, May 9th.

Elicio Therapeutics, Inc. today announced that it will be sharing new preliminary data from the ongoing AMPLIFY-7P Phase 1/2 study in a poster presentation at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting, being held May 31-June 4, 2024 in Chicago, IL.

DarioHealth Corp. announced new research published in the leading peer-reviewed journal for digital health and medicine, Journal of Internet Medicine demonstrating a clinically significant reduction in blood glucose levels for members using Dario to manage weight alongside diabetes.

Vistagen today announced positive results from a Phase 2A pilot study of PH15, an investigational pherine nasal spray, for improvement of psychomotor impairment caused by mental fatigue.

Medigene AG presents a comprehensive overview of its lead candidate MDG1015, a first-in-class 3rd generation T cell receptor engineered T cell therapy, at CHI’s 8th Annual Immuno-Oncology Summit Europe from April 23-25, 2024, in London.